Q3071752 (Q3071752): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Edited by the infer coords bot - inferring coordiantes from postal codes)
(‎Created claim: summary (P836): Icosagen Cell Factory OÜ commercialises patented technologies through the development and production of antibodies to diagnostic and pharmaceutical companies. In the chosen business model, personal communication with customers not only influences the technological performance of the sales results. The main means of developing a relationship network in the US drug development market, and thereby promoting export sales of the service, is to presen...)
Property / summary
 
Icosagen Cell Factory OÜ commercialises patented technologies through the development and production of antibodies to diagnostic and pharmaceutical companies. In the chosen business model, personal communication with customers not only influences the technological performance of the sales results. The main means of developing a relationship network in the US drug development market, and thereby promoting export sales of the service, is to present the company at the largest US drug development fairs and conferences. (English)
Property / summary: Icosagen Cell Factory OÜ commercialises patented technologies through the development and production of antibodies to diagnostic and pharmaceutical companies. In the chosen business model, personal communication with customers not only influences the technological performance of the sales results. The main means of developing a relationship network in the US drug development market, and thereby promoting export sales of the service, is to present the company at the largest US drug development fairs and conferences. (English) / rank
 
Normal rank
Property / summary: Icosagen Cell Factory OÜ commercialises patented technologies through the development and production of antibodies to diagnostic and pharmaceutical companies. In the chosen business model, personal communication with customers not only influences the technological performance of the sales results. The main means of developing a relationship network in the US drug development market, and thereby promoting export sales of the service, is to present the company at the largest US drug development fairs and conferences. (English) / qualifier
 
point in time: 16 August 2021
Timestamp+2021-08-16T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Revision as of 12:31, 16 August 2021

Project Q3071752 in Estonia
Language Label Description Also known as
English
No label defined
Project Q3071752 in Estonia

    Statements

    0 references
    32,943.00 Euro
    0 references
    57,559.0 Euro
    0 references
    57.23 percent
    0 references
    1 May 2019
    0 references
    28 February 2022
    0 references
    Icosagen Cell Factory OÜ
    0 references

    58°22'0.84"N, 26°39'47.41"E
    0 references
    61713
    0 references
    Icosagen Cell Factory OÜ kommertsialiseerib patenteeritud tehnoloogiaid läbi antikehade arendamise ja tootmise teenuse osutamise diagnostika- ja farmaatsiaettevõtetele. Valitud ärimudeli puhul mõjutab müügitulemusi tehnoloogilisele võimekusele lisaks ka isiklik suhtlus klientidega. USA ravimiarenduse turul suhtevõrgustiku arendamise ja seeläbi teenuse eksportmüügi edendamise peamiseks vahendiks on ettevõtte esitlemine suurimatel USA ravimiarenduse messidel ja konverentsidel. (Estonian)
    0 references
    Icosagen Cell Factory OÜ commercialises patented technologies through the development and production of antibodies to diagnostic and pharmaceutical companies. In the chosen business model, personal communication with customers not only influences the technological performance of the sales results. The main means of developing a relationship network in the US drug development market, and thereby promoting export sales of the service, is to present the company at the largest US drug development fairs and conferences. (English)
    16 August 2021
    0 references

    Identifiers

    2014-2020.5.01.19-1075
    0 references